摘要
Background: Breast cancer stem cells (BCSCs) play an important role in cancer recurrence and metastasis. The aggressiveness is further amplified by the overexpression of immune checkpoints on cancer cells, primarily CD47 and PD-L1, which enable evasion of macrophage and T cell-mediated immune surveillance. Therefore, innovative strategies targeting both bulk cancer cells and BCSCs, while simultaneously activating the host immune system, may have the potential to eradicate breast cancer. Aim: To develop and evaluate two BCSC-targeting strategies: (i) CSC-targeted intracellular delivery of a standard chemotherapeutic agent and a BCSC inhibitor; and (ii) its integration with immune checkpoint inhibitors, including newly developed anti-CD47 siRNA lipid nanoparticles (siCD47-LNPs), or with clinically approved anti-PD-L1 antibodies to activate innate and adaptive immunity, thereby ensuring durable, effective cancer clearance. Methods: Hyaluronic acid-functionalised pH-sensitive liposomes (HA-pSL) and clinically used non-pH-sensitive DOXIL-like liposomes were prepared to deliver a BCSC inhibitor (bufalin) and doxorubicin as a chemotherapy pSL-cocktail. In parallel, siCD47-LNPs were developed. The therapeutic potential of pSL-cocktail alone or in combination with siCD47-LNPs or anti-PD-L1 antibody was comprehensively investigated in BC cell lines, spheroids and patient-derived organoids before being assessed in various orthotopic tumour models. Results and discussion: The pSL-cocktail outperformed all control formulations both in vitro and in vivo. It markedly enhanced cytotoxicity in cell lines, reducing the DOX IC₅₀ by 5-fold compared with the npSL-cocktail. The pSL-cocktail effectively suppressed tumour stemness, evidenced by significantly reduced cell migration, mammosphere formation and self-renewal capacity. In spheroids, HA-pSL displayed rapid deep penetration. In organoids, the pSL-cocktail induced structural disruption and profound cytotoxicity. The pSL-cocktail induced robust immunogenic cell death, while siCD47-LNPs effectively silenced CD47 expression. In vivo, the pSL-cocktail was well-tolerated, demonstrated high tumour accumulation, and superior tumour suppression compared with monotherapy and free-drug combination. The pSL-cocktail, either with siCD47-LNPs or anti-PD-L1, exhibited the strongest antitumour activity, achieving complete growth suppression or even 52% tumour shrinkage, along with enhanced macrophage and DC activation and T-cell infiltration. Conclusion: The CSC-targeting chemotherapeutic nanococktail achieved synergistic anti-tumour efficacy with effective BCSCs suppression. The nanococktail potentiated both CD47-targeted siRNA and anti-PD-L1 immunotherapy, resulting in enhanced therapeutic efficacy.